Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.51 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512138 | 0.85 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Hydrochloric Acid SCHEMBL30512140 | 0.82 | CACNA2D1 (0.53) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL20097532 | 0.81 | CACNA2D1 (0.51) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL7980052 | 0.80 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL15698640 | 0.80 | CACNA2D1 (0.58) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL25812326 | 0.79 | MMP1 (0.39) | ALDH1A1PRKCAPRKCE | |
| Hydrochloric Acid SCHEMBL30695404 | 0.78 | CACNA2D1 (0.56) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL25734261 | 0.78 | CACNA2D1 (0.60) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL25735046 | 0.78 | CACNA2D1 (0.60) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4476054 | 0.77 | CACNA2D1 (0.51) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | LIU, MIAO (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248837-A1 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | VIP, GHITM, MYCBP | CACNA2D1 4091/4885CACNB3 2902/4885CACNA1C 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.